Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Advances in the structural studies of antibiotic potentiators against Escherichia coli.

Blankson GA, Parhi AK, Kaul M, Pilch DS, LaVoie EJ.

Bioorg Med Chem. 2019 Aug 1;27(15):3254-3278. doi: 10.1016/j.bmc.2019.06.003. Epub 2019 Jun 4. No abstract available.

PMID:
31235265
2.

Structure-activity relationships of potentiators of the antibiotic activity of clarithromycin against Escherichia coli.

Blankson G, Parhi AK, Kaul M, Pilch DS, LaVoie EJ.

Eur J Med Chem. 2019 Sep 15;178:30-38. doi: 10.1016/j.ejmech.2019.05.075. Epub 2019 May 29.

PMID:
31173969
3.

β-Lactam Antibiotics with a High Affinity for PBP2 Act Synergistically with the FtsZ-Targeting Agent TXA707 against Methicillin-Resistant Staphylococcus aureus.

Ferrer-González E, Kaul M, Parhi AK, LaVoie EJ, Pilch DS.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e00863-17. doi: 10.1128/AAC.00863-17. Print 2017 Sep.

4.

Structural Flexibility of an Inhibitor Overcomes Drug Resistance Mutations in Staphylococcus aureus FtsZ.

Fujita J, Maeda Y, Mizohata E, Inoue T, Kaul M, Parhi AK, LaVoie EJ, Pilch DS, Matsumura H.

ACS Chem Biol. 2017 Jul 21;12(7):1947-1955. doi: 10.1021/acschembio.7b00323. Epub 2017 Jun 16.

5.

Combining the FtsZ-Targeting Prodrug TXA709 and the Cephalosporin Cefdinir Confers Synergy and Reduces the Frequency of Resistance in Methicillin-Resistant Staphylococcus aureus.

Kaul M, Mark L, Parhi AK, LaVoie EJ, Pilch DS.

Antimicrob Agents Chemother. 2016 Jun 20;60(7):4290-6. doi: 10.1128/AAC.00613-16. Print 2016 Jul.

6.

TXA709, an FtsZ-Targeting Benzamide Prodrug with Improved Pharmacokinetics and Enhanced In Vivo Efficacy against Methicillin-Resistant Staphylococcus aureus.

Kaul M, Mark L, Zhang Y, Parhi AK, Lyu YL, Pawlak J, Saravolatz S, Saravolatz LD, Weinstein MP, LaVoie EJ, Pilch DS.

Antimicrob Agents Chemother. 2015 Aug;59(8):4845-55. doi: 10.1128/AAC.00708-15. Epub 2015 Jun 1.

7.

Inhibition of RND-type efflux pumps confers the FtsZ-directed prodrug TXY436 with activity against Gram-negative bacteria.

Kaul M, Zhang Y, Parhi AK, Lavoie EJ, Pilch DS.

Biochem Pharmacol. 2014 Jun 1;89(3):321-8. doi: 10.1016/j.bcp.2014.03.002. Epub 2014 Mar 14.

PMID:
24637241
8.

Pharmacokinetics and in vivo antistaphylococcal efficacy of TXY541, a 1-methylpiperidine-4-carboxamide prodrug of PC190723.

Kaul M, Mark L, Zhang Y, Parhi AK, LaVoie EJ, Pilch DS.

Biochem Pharmacol. 2013 Dec 15;86(12):1699-707. doi: 10.1016/j.bcp.2013.10.010. Epub 2013 Oct 20.

PMID:
24148278
9.

Phenyl substituted 3-hydroxypyridin-2(1H)-ones: inhibitors of influenza A endonuclease.

Parhi AK, Xiang A, Bauman JD, Patel D, Vijayan RS, Das K, Arnold E, Lavoie EJ.

Bioorg Med Chem. 2013 Nov 1;21(21):6435-46. doi: 10.1016/j.bmc.2013.08.053. Epub 2013 Sep 4.

PMID:
24055080
10.

An FtsZ-targeting prodrug with oral antistaphylococcal efficacy in vivo.

Kaul M, Mark L, Zhang Y, Parhi AK, Lavoie EJ, Pilch DS.

Antimicrob Agents Chemother. 2013 Dec;57(12):5860-9. doi: 10.1128/AAC.01016-13. Epub 2013 Sep 16.

11.

Crystallographic fragment screening and structure-based optimization yields a new class of influenza endonuclease inhibitors.

Bauman JD, Patel D, Baker SF, Vijayan RS, Xiang A, Parhi AK, Martínez-Sobrido L, LaVoie EJ, Das K, Arnold E.

ACS Chem Biol. 2013 Nov 15;8(11):2501-8. doi: 10.1021/cb400400j. Epub 2013 Sep 13.

12.

Antibacterial activity of quinoxalines, quinazolines, and 1,5-naphthyridines.

Parhi AK, Zhang Y, Saionz KW, Pradhan P, Kaul M, Trivedi K, Pilch DS, LaVoie EJ.

Bioorg Med Chem Lett. 2013 Sep 1;23(17):4968-74. doi: 10.1016/j.bmcl.2013.06.048. Epub 2013 Jun 26.

13.

Enterococcal and streptococcal resistance to PC190723 and related compounds: molecular insights from a FtsZ mutational analysis.

Kaul M, Zhang Y, Parhi AK, Lavoie EJ, Tuske S, Arnold E, Kerrigan JE, Pilch DS.

Biochimie. 2013 Oct;95(10):1880-7. doi: 10.1016/j.biochi.2013.06.010. Epub 2013 Jun 25.

14.

A bactericidal guanidinomethyl biaryl that alters the dynamics of bacterial FtsZ polymerization.

Kaul M, Parhi AK, Zhang Y, LaVoie EJ, Tuske S, Arnold E, Kerrigan JE, Pilch DS.

J Med Chem. 2012 Nov 26;55(22):10160-76. doi: 10.1021/jm3012728. Epub 2012 Oct 26.

15.

In vivo studies of the SERT-selective [18F]FPBM and VMAT2-selective [18F]AV-133 radiotracers in a rat model of Parkinson's disease.

Wang JL, Oya S, Parhi AK, Lieberman BP, Ploessl K, Hou C, Kung HF.

Nucl Med Biol. 2010 May;37(4):479-86. doi: 10.1016/j.nucmedbio.2010.01.006.

16.

Synthesis of the Mixed Acetal Segment of S-Glyceroplasmalopsychosine.

Parhi AK, Mootoo DR, Franck RW.

Tetrahedron. 2008 Oct 13;64(42):9821-9827.

17.

In vivo characterization of a series of 18F-diaryl sulfides (18F-2-(2'-((dimethylamino)methyl)-4'-(fluoroalkoxy)phenylthio)benzenamine) for PET imaging of the serotonin transporter.

Wang JL, Parhi AK, Oya S, Lieberman B, Kung HF.

J Nucl Med. 2009 Sep;50(9):1509-17. doi: 10.2967/jnumed.108.060723. Epub 2009 Aug 18.

18.

Synthesis of Fluorescent Probes based on Stilbenes and Diphenylacetylenes targeting β-Amyloid Plaques.

Parhi AK, Kung MP, Ploessl K, Kung HF.

Tetrahedron Lett. 2008;49(12):3395-3399.

19.

2-(2'-((Dimethylamino)methyl)-4'-(3-[(18)F]fluoropropoxy)-phenylthio)benzenamine for positron emission tomography imaging of serotonin transporters.

Wang JL, Parhi AK, Oya S, Lieberman B, Kung MP, Kung HF.

Nucl Med Biol. 2008 May;35(4):447-58. doi: 10.1016/j.nucmedbio.2008.02.009.

20.

2-(2'-((dimethylamino)methyl)-4'-(fluoroalkoxy)-phenylthio)benzenamine derivatives as serotonin transporter imaging agents.

Parhi AK, Wang JL, Oya S, Choi SR, Kung MP, Kung HF.

J Med Chem. 2007 Dec 27;50(26):6673-84. Epub 2007 Dec 4.

21.

A Weinreb nitrile oxide and nitrone for cycloaddition.

Parhi AK, Franck RW.

Org Lett. 2004 Sep 2;6(18):3063-5.

PMID:
15330588

Supplemental Content

Loading ...
Support Center